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Abstract 
Antibiotics are the wonder discoveries to combat microbes. For decades, multiple varieties of antibiotics have been used for 
therapeutic purposes in hospital settings and communities throughout the world. Unfortunately, bacteria have become 
resistant to commonly prescribed antibiotics. This review aims to explore the development, challenges, and the current state 
of antibiotic resistance available literature in Malaysia. Recently published data from Pubmed, Scopus, Google scholar’s 
and other internet source publication on the antibiotic resistance of gram-negative bacteria were further reviewed and 
analysed in this study. This review reiterates the antibiotic resistance among the gram-negative bacteria is increasing and 
they are becoming resistant to nearly all groups of antibiotics. The antibiotic treatments are minimal and hard to treat in 
multi-drug resistance bacterial infection, resulting in morbidity and mortality. The prevalence rate of antibiotic resistance 
from the literature suggests that educating patients and the public is essential to prevent and control the spread of antibiotic 
resistance. In particular, there is an urgent need for a surveillance system of regular monitoring on the microbiomes, the 
discovery of novel antibiotics and therapeutic application of antibiotics are mandatory. 
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1. INTRODUCTION 
       
Antimicrobial resistance creates a significant 
health problem worldwide by its various factors, 
especially in hospital settings. The primary factors 
include the exposures to cross infection and broad-
spectrum antimicrobials. Understanding the extent and 
type of antimicrobial use might help in developing an 
awareness of antibiotic resistance. Becoming resistant 
to multiple antibiotics is a serious threat of gram-
negative bacteria through out the world. These 
resistant bacteria most of the times prolong the 
treatment procedures and also transfer its’ genetic 
material to other bacteria to transform the bacteria into 
a drug-resistant strain (World Health Organization, 
2017,  27 February). The occurrences of multidrug-
resistant (MDR) pathogens are contineously 
increasing although many different ways are 
employed to combat the antibiotic resistance of the 
pathogens (Laxminarayan et al., 2013). Millions of 
lives are being saved by transforming antibiotics into 
medicine while prevalence of antibiotic resistance is 
reported worldwide (Golkar, Bagasra, & Pace, 2014). 
Antibiotics play essential roles in achieving significant 
advances in medicine and surgery through saving 
millions of patients’ lives. Many decades after the first 
patient was treated with antibiotics yet bacterial 
infections are a major threat to health managements 
(Spellberg & Gilbert, 2014). Inappropriate use of 
antibiotic therapy associated with disease can lead to 
the development of drug-resistant strains (Deris, 
2015).  
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The antibiotic resistance crisis is due to the 
overuse and misuse, along with incapability to develop 
new drug by the pharmaceutical companies. The 
Centres for Disease Control and Prevention (CDC) has 
classified some bacteria as presenting urgent, 
dangerous, and concerning threats. Antibiotic 
resistance gram-negative bacteria including extended 
spectrum β-lactamases (ESBLs) and multidrug-
resistant have emerged and spread throughout 
Malaysia. 
 
 
2. METHODS 
 
2.1 Literature search, definition and selection 
strategy 
In this article, it was reviewed and summarized 
the current critical knowledge on the epidemiolocal as 
well as molecular characterization of antibiotic 
resistance in Malaysia. The National Surveillance of 
Antibiotic Resistance (NSAR) report by the Ministry 
of Health, Malaysia have revealed data until 2017 
from 39 hospital-based microbiology laboratories 
which included thirty-seven microbiology laboratories 
of government hospitals, and 2 hospital based 
university. The published articles in Pubmed, Scopus, 
Google scholar’s and other recent internet source 
publication on the antibiotic resistance of gram-
negative bacteria were further reviewed and included 
in this study. 
3. Result and Discussion 
The most critical group of gram-negative bacteria 
which causes diseases and become resistant to 
multiple antibiotics was highlighted. The multidrug 
resistant bacteria such as 
Acinetobacter, Pseudomonas and various 
Enterobacteriaceae including Klebsiella, and E. coli 
can cause severe and often deadly infections those are 
frequently reported in the hospitals and clinics. 
However, many studies reported that gram-negative 
bacteria showed multiple-antibiotic resistance due to 
misuse of antibiotics, longer duration of prior 
antimicrobial therapy and a higher number of 
antimicrobial applications to control infections. 
Highest and medium priority categories of bacteria 
those cause bloodstream infections and pneumonia 
was reviewed under current scope. This study would 
give a clear view on the urgency (critical, high and 
medium priority) of new antibiotics development. It 
was also presented the most dominant bacteria causing 
various types of diseases throughout the world as well 
as in Malaysia. 
Acinetobacter 
Acinetobacter is a complex genus with the 
existence of multiple species. The species commonly 
cause nosocomial infections, pneumonia, catheter-
associated bacteremia, soft tissue and urinary tract 
infections (Wong et al., 2017). Acinetobacter spp. 
described as natural transformable bacteria and can 
become resistant to many different classes of 
antibiotics (Perez et al., 2007). 
In 2014, fifty-four Acinetobacter isolates (72.2%) 
obtained from a tertiary hospital in Terengganu, 
Malaysia. This study revealed the  resistance rate of 
tetracycline (87%), piperacillin-tazobactam (72.2%), 
cefotaxime (72.2%), ceftazidime (72.2%), cefepime 
(72.2%), levofloxacin (70.4%), ampicillin-sulbactam 
(68.5%). In addition, gentamicin (66.7%), 
ciprofloxacin (66.7%), tobramycin (64.8%), 
doxycycline (61.1%) and amikacin (57.4%). The 
isolates also showed high resistance to carbapenems as 
77.8% of the isolates found to be resistant to 
meropenem and 74.1% to imipenem. The MIC values 
of carbapenem-resistant isolates was >32 μg/mL. 39 
(72.2%) isolates out of 54 strains were multidrug-
resistant (MDR) means resistant to more than three 
classes of antibiotics against bacteria. All MDR 
isolates were resistant to meropenem and imipenem. 
Polymyxin resistance which was determining the MIC 
values for polymyxin B. of the 54 isolates. The 
resistant was 25.9% to polymyxin (MIC ≥ 4 μg/mL, 
and four isolates had MIC values of >128 μg/mL for 
polymyxin B. These 14 polymyxin-resistant isolates 
classified as extensive drug resistant (XDR) isolates 
(Lean et al., 2014). Moreover, a molecular study on 40 
isolates of Acinetobacter spp.were resistant to 
ciprofloxacin (55%), imipenem (67.5%), amikacin 
(50%), gentamicin (52.5%), ampicillin (75%), 
ceftazidime (60%), meropenem (92.5%), piperacillin 
(77.5%), cefoperazone (60%) and 
tazobactam/piperacillin (67.5%) respectively. 
Meropenem showed the maximum resistance (92.5%) 
followed by piperacillin (77.5%) and ampicillin 
(75%). In addition, 5% Acinetobacter strains were 
resistant to one antibiotic, 10% strains to two 
antibiotics, and 85% strains to three or more 
antibiotics (Nazmul, Jamal, & Fazlul, 2012). National 
Surveillance of Antibiotic Resistance, Malaysia have 
reported that increase resistance rates of various types 
antibiotics from 2013 to 2017. Studies showed that 
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ampicillin/sulbactam, ceftazidime, imipenem, 
meropenem, gentamicin, amikacin, ciprofloxacin, 
cefoperazone/sulbactam, and piperacillin/tazobactam 
were resistance to Acinetobacter spp. The resistance 
rate of ampicillin/sulbactam noted to slightly increase 
to 53.8% in 2015 compared to 53.3 in 2014. The 
highest resistance was observed for meropenem 58.8% 
and the least resistance were detected for colistin 0.8% 
while in 2016 Meropenem resistance increased to 
60.8% (M. o. H. Institute for Medical Research, 
Malaysia, 2017, 15th September). 
In 2016, antibiotic susceptibility test by S.Y. Ng 
observed 15 out of 22 isolates (68.18%) categorized as 
multidrug resistant organisms (MDROs) due to 
resistant by one agent in three or more antibiotic. The 
significant strains were resistant towards cephalexin 
(95.45%), followed by enrofloxacin (59.09%), 
amoxicillin-clavulanic acid (54.55%), 
sulphamethoxazole-trimethoprim (54.55%) and 
tetracycline (50%) respectively. Five out of six A. 
Baumannii isolates (83.33%) were classified as MDR 
by antibiotic susceptibility test, and all (6) 
Acinetobacter baumannii isolates were resistance to 
all antibiotics. From the antibiotic susceptibility 
profile, all the six A. Baumannii isolates (100%) were 
resistant to cephalexin. Among the six isolates, one 
strain was resistant to tetracycline and enrofloxacin,  
two strains were resistant to sulphamethoxazole-
trimethoprim, and rest three isolates were resistant to 
amoxicillin-clavulanic acid (Ng, Abdul Aziz, Bejo, & 
Dhaliwal, 2016). In 2007, a mixed growth of 
imipenem-resistant strain of K. pneumonia, 
Acinetobacter spp. and a Proteus spp. was observed at 
University of Malaya Medical Centre (UMMC), Kuala 
Lumpur, Malaysia. The Acinetobacter spp. was 
resistant to imipenem, ceftazidime, cefuroxime, 
cefotaxime, cefepime, and meropenem respectively 
while sensitive to a number of antibiotics (amikacin, 
gentamicin, netilmicin, ciprofloxacin, cefoperazone–
sulbactam and ampicillin-sulbactam) 
(Palasubramaniam, Karunakaran, Gin, Muniandy, & 
Parasakthi, 2007).  
The presence of multidrug-resistance (MDR) in 
Acinetobacter baumannii strains was observed in a 
tertiary-care center, Subang Jaya, Selangor, Malaysia 
by Jayakayatri in 2016. These studies revealed that the 
strains of Acinetobacter baumannii were resistance to 
11 types of antimicrobials (polymyxin B, 
ampicillin/sulbactam, ceftazidime, meropenem, 
imipenem, amikacin, gentamicin, ciprofloxacin, 
levofloxacin, trimethoprim/sulfamethoxazole, and 
tigecycline). A total number of 53% strains were 
classified as multidrug-resistance (resistant to 4 or 
more antibiotics) (Desa, Yong, Navaratnam, 
Palanisamy, & Wong, 2016). The accumulated study 
data on Acinetobacter can be beneficial for proper 
antibiotic treatments and infections control 
management. According to the World Health 
Organization (WHO), carbapenem-resistant for 
Acinetobacter baumanni are in critical situations 
(World Health Organization, 2017,  27 February). 
Over the past decades, different types of antibiotics 
including meropenem, tetracycline, ceftazidime, and 
cefuroxime have shown the highest resistance to 
Acinetobacter species. 
Meropenem shows the highest frequency of 
resistance among all used antibiotics. The highest 
antibiotic resistance rate of Acinetobacter spp. has 
shown in table 1 from the accumulated data observed 
in Malaysia. An increased in resistant rate was noted 
for imipenem (61.7%), meropenem (61%), gentamicin 
(53.2%), amikacin and (49.8%), in 2017 compared to 
2010. An increasing trend of antibiotic resistance was 
observed among the clinical samples of Acinetobacter 
spp. between 2010 and 2017. Among the 5 used 
antibiotics, imipenem 61.7% indicated the highest 
resistant in 2017 while 54.8% in 2010. The trends of 
antibiotic resistance are increasing among the used 
antibiotics past 7 years (2010 to 2017) have shown in 
figure 1. Although The lowest resistance was observed 
for gentamicin (53.2%) in 2017 but 48% in 2010 (M. 
o. H. Institute for Medical Research, Malaysia, 2017, 
15th September).  
Pseudomonas aeruginosa 
Pseudomonas aeruginosa commonly caused 
different types of disease including community-
acquired and nosocomial-acquired pneumonia. Over 
the years, the development of Pseudomonas 
aeruginosa resistance is increasing globally due to the 
overuse of antibiotics (Yayan, Ghebremedhin, & 
Rasche, 2015). The resistance of P. aeruginosa occurs 
after 3–4 days of the initiation of treatment (Juayang 
et al., 2017). The most severe nosocomial infection 
correlates with increased resistance to antibiotics with 
high morbidity and mortality (Sonmezer et al., 2016). 
 In 2007, a multi-resistant strain of Pseudomonas 
aeruginosa was sensitive to polymyxin B, 
intermediate to amikacin and resistant to netilmicin, 
piperacillin, piperacillin-tazobactam, imipenem, 
ceftazidime, cefoperazone, ciprofloxacin, gentamicin, 
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and meropenem (Palasubramaniam et al., 2007). In 
addition, fifty-four clinical isolates of Pseudomonas 
aeruginosa from Selayang Hospital, Malaysia has 
revealed the rates of antimicrobial resistance. The 
strains were resistant 9.25 % to ciprofloxacin, 
meropenem, and cefepime respectively. The resistance 
rates were observed for amikacin 12.97%, tazobactam 
27.78%, imipenem 16.67%, cefoperazone 27.78%, 
ceftazidime 29.63%, gentamicin 14.82% and 50% to 
piperacillin (Fazlul, Zaini, Rashid, & Nazmul, 2011). 
Moreover, a study on P. aeruginosa at tertiary care 
hospital in Malaysia by Raja et al., described the rates 
of antimicrobial resistance of 12.9% gentamicin, 
10.1% netilmicin, 10.9% ceftazidime, 11.3% 
ciprofloxacin, 9.9%  imipenem, 10.8% piperacillin, 
9.4% piperacillin-tazobactam, 6.73% amikacin and 
0% to polymyxin B while 5.74% of the strains were 
found to be (MRD) multidrug-resistant (Raja & Singh, 
2007). 
Pseudomonas aeruginosa, the common pathogen 
causes nosocomial infections. In 2009, a molecular 
characterization was determined for 48 clinical 
isolates of P. aeruginosa from 6 public hospitals in 
Malaysia. The obtained data was analyzed by 
antimicrobial susceptibility test and DNA 
fingerprinting techniques. In these study P. 
aeruginosa isolates were resistant to tetracycline 
(73%), chloramphenicol (60%), cefotaxime (40%), 
ceftriaxone (31%), cefoperazone (29%), ticarcillin 
(25%), piperacillin (23%), and imipenem (21%). Less 
than 20% of P. aeruginosa were sensitive to 
ceftazidime, gentamicin, cefepime, ciprofloxacin, 
amikacin, piperacillin-tazobactam, and aztreonam. 
Moreover, 33 strains of P. aeruginosa (68.75 %) were 
multidrug resistant, and aztreonam was the most 
effective antibiotic (Lim et al., 2009). In a similar 
study, ninety (90) randomly selected non-replicate 
imipenem-resistant P. aeruginosa isolates were 
collected from UMMC, a university teaching hospital 
at Kuala Lumpur, Malaysia. All these clinical 
specimens were from nonrepetitive patients (57 
females and 33 males). These study reported that 
antibiotic resistance profiles of P. aeruginosa isolate 
by using disk-diffusion tests. Ceftazidime 63% 
showed the highest resistant followed by amikacin 
62%  and least resistant to netilmicin 48% (Khosravi, 
Tee Tay, & Vadivelu, 2010) in P. aeruginosa. 
National Surveillance of Antimicrobial Resistance 
(NSAR), 2017 reported that the imipenem 7.8% 
showed the highest resistance in 2017 while 9.1% in 
2016. Among the used antibiotics for P. aeruginosa, 
only gentamicin has increased in resistance pattern 
from 3.1% in 2016 to 5.6% in 2017. The least 
resistance to colistin 0.3% was observed in 2015 while 
2.7% in 2013 (M. o. H. Institute for Medical Research, 
Malaysia,, 2016).  Different range of resistance rate of 
amikacin (3.5%),  ceftazidime (6.9%), cefepime 
(5.4%) and meropenem (6.6%)  was observed in 2017 
compared to 2017 (M. o. H. Institute for Medical 
Research, Malaysia, 2017, 15th September). 
According to the World Health Organization (WHO), 
carbapenem-resistant for Pseudomonas aeruginosa is 
in critical situations (World Health Organization, 
2017,  27 February). 
Among the different types of antibiotics, 
ceftazidime showed the higest resistance to 
P.aeruginosa followed by piperacillin and least 
resistance by colistin between 2002 and 2017. The 
variation of antibiotic resistance rate was observed 
among all used antibiotics since 2002 to 2017 (Figure 
2). Meropenem (8.1%), ceftazidime (8.9%), and 
cefepime (5.5%) showed the decreasing trends in 2016 
compared to resistance in 2015 (M. o. H. Institute for 
Medical Research, Malaysia, 2017, 21st September,).  
Klebsiella species 
Klebsiella species causes nosocomial and 
community-acquired infections worldwide 
(Moradigaravand, Martin, Peacock, & Parkhill, 2017). 
Severe lung and bloodstream infections which are 
challenging to treat due to its multidrug resistance 
properties of  Klebsiella pneumoniae  (Jana et al., 
2017).  
The prevalence and antibiotic susceptibility of 
Gram-negative bacteria among infants admitted to the 
neonatal intensive care unit (NICU) in a tertiary 
teaching hospital in Malaysia described a total of 34 
stool specimens obtained from infants of multidrug-
resistant k. pneumoniae unusually high resistance to 
polymyxins. Three colistin resistant k. 
pneumoniae have also detected by E-test analysis 
(Low et al., 2017). Thirty-nine isolates of k. 
pneumoniae were resistant to more than three 
antimicrobial classes which classified as multidrug-
resistant (MDR). Ampicillin-resistance was highest in 
Klebsiella spp. (84.3%) (Nor et al., 2015) described 
out of 721 gram-negative isolates  and 21.2% was 
Klebsiella spp. 
A recent study of 93 Malaysian patients who was 
affected by the multidrug-resistant of K. Pneumonia 
isolates at University of Malaya Medical Center, 
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Kuala Lumpur, Malaysia. These reports demonstrated 
higher resistance rates of ampicillin (100%) followed 
by aztreonam (98.9%) and cephalosporins including 
ceftriaxone (100%), cefoperazone (100%), cefotaxime 
(100%) showing the maximum resistance followed by 
cefuroxime (98.9%) and ceftazidime (97.8%) against 
K. Pneumonia. Also, the isolates were susceptible to 
cefoxitin, except three (3.2%) isolates (strain K106, 
M40, and NDM-2012). The resistance rate of 
piperacillin-tazobactam (43%) was lower then other β-
lactam/β-lactamase inhibitor combinations (94.6% for 
amoxicillin-clavulanate and ampicillin-sulbactam 
98.9%). Non-susceptibility to 
trimethoprim/sulfamethoxazole, gentamicin and 
amikacin were observed in 90.3%, 74% and 5.4% of 
the isolates respectively (Al-Marzooq, Yusof, & Tay, 
2015). In addition, imipenem-resistant strain of K. 
pneumonia in 2007 by Selvi at UMMC, Kuala Lumpur 
Malaysia confirmed resistant to the extended-
spectrum β-lactams and sensitive to gentamicin, 
amikacin, and netilmicin (Palasubramaniam et al., 
2007). 
In 2017, carbapenem-resistant of K. pneumoniae 
were resistant to tetracycline except two strains were 
intermediate, but only one strain was resistant to 
tigecycline in Malaysia. Among all the isolates, 
47.06% strains were resistant to cephalosporin groups 
of antibiotics while all bacterial strains were sensitive 
to colistin and resistance to atleast one carbapenem 
(MIC = 4 - >32 μg/ml) antibiotic. Resistance to 
imipenem significantly associated with in-hospital 
mortality (P = 0.043). Two strains (K/1311-35 and 
K/1304-16) were resistant to imipenem (MIC = 4 – 6 
μg/ml) while sensitive to meropenem and ertapenem. 
One isolates of K. pneumoniae (K/1312-3) was 
sensitive to imipenem but resistant to meropenem and 
ertapenem (MIC = 6 – 16 μg/ml). Again, three strains 
(17.65%) were resistant to aminoglycoside group of 
antibiotics (MIC = 24 - >256 μg/ml for gentamicin and 
tobramycin; MIC = 64 - >256 μg/ml for amikacin) 
while thirteen strains (76.47%) were resistant to all 
types of fluoroquinolones antibiotics (MIC = 8 - >32 
μg/ml) (Low et al., 2017). 
Klebsiella pneumonia showed an increasing trend 
of antibiotic resistance over the years. National 
surveillance of antibiotic resistance reported that the 
resistant to carbapenems, namely imipenem (2.4%) 
and meropenem (2.8%) increased in 2015 compared to 
2014 while cefuroxime showed higher resistance 
(28.4%) between 2013 and 2017. The least resistance 
was observed by imipenem 1.3% in 2013 past 5 years. 
The resistance rates of aminoglycosides namely 
gentamicin and amikacin remain reasonably stable 
over the years since 2013 to 2015. The resistant rate of 
carbapenems (imipenem 2.7% and meropenem 2.9%) 
were increased in 2017 compared to while imipenem 
2.3% and meropenem 2.6% in 2016 (M. o. H. Institute 
for Medical Research, Malaysia,, 2016). The 
emergence of 321 carbapenem-resistant Klebsiella 
pneumonia (CRKP) were resistant to 2nd and 3rd 
generation cephalosporin tested included cefuroxime, 
cefepime, cefotaxime, ceftazidime, cefoperazone, 
trimethoprim-sulfamethoxazole, and amoxicillin-
clavulanate in 2015.  A few CRKP isolates of 5/13 
(38.5%) were susceptible to aminoglycosides groups 
(gentamicin, amikacin, and netilmicin). Meanwhile, 
4/13 (30.7%) isolates were susceptible to 
ciprofloxacin and 4/30 (13.3%) to piperacillin–
clavulanate. Eight isolates (61.5%) were resistant to all 
tested antibiotics except colistin and tigecycline 
(Hamzan, Yean, Rahman, Hasan, & Rahman, 2015).  
Among all the recent studies on Klebsiella 
pneumonia have shown high resistance impact on the 
different antibiotics namely polymixins, ampicillin, 
extended-spectrum β-lactams, tetracycline and 
ampicillin/sulbactam whereas the least resistance to 
imipenem, meropenem, and amikacin. 
Escherichia coli  
Escherichia coli is the most common agent of 
various types of infection especially urinary tract 
infections (UTI), cholecystitis, cholangitis, diarrhoea, 
neonatal meningitis and pneumonia etc. The leading 
cause of bacteremia is due to Gram-negative 
Escherichia coli (Woodford, Turton, & Livermore, 
2011). 
Noor Safina included a total of 721 cases to 
identify the resistance rates of gram-negative bacteria  
in 2015. Among all the patients 54% were male, and 
46% were female. The 3 most common organisms 
isolated in the total population, Escherichia coli 
(41.6%) were the most prevalent organisms in both the 
prophylaxis (60.7%) and no prophylaxis (39.8%). 
Among the antibiotic resistance, E.coli showed a 
higher resistance to ampicillin (67.7%), cefuroxime 
(15.3%) and gentamicin (7.3%) respectively (Nor et 
al., 2015). 
In 2009, a study of Lim and his colleagues 
examined 47 nonrepeat E. coli isolates collected in 
2004 from 47 different patients of 5 public hospitals 
located in different location of Malaysia. The 
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participating hospitals were Kota Bharu Hospital (n = 
10), Sultanah Aminah Hospital (n = 23), Kuala 
Lumpur Hospital (n = 10), Ipoh Hospital (n = 2), and 
Queen Elizabeth Hospital (n = 2). The data indicated a 
high prevalence of resistance to ampicillin (77%), 
piperacillin (64%), tetracycline (53%), trimethoprim-
sulfamethoxazole (43%), cefoperazone, kanamycin 
(30%), Nalidixic acid (28%), chloramphenicol (26%), 
ciprofloxacin (23%), gentamicin (21%), amoxicillin-
clavulanic acid (17%), ceftriaxone ceftazidime, and 
aztreonam 11% each, and amikacin 2% among all the 
E. coli isolates (Lim et al., 2009). Among them, 36 
isolates (76.5%) were multidrug-resistant while 
cephalosporin resistant isolates were also resistant to 
ampicillin and 71% of them resistant to tetracycline. A 
large number of strains (72%) were resistant to 
aminoglycosides (Lim et al., 2009). Meanwhile, out of 
76 gram-negative isolates of E. coli were resistant to 
amoxicillin/clavulanate (30.8%, n = 16), ceftriaxone 
(42.3%, n = 22), ceftazidime (28.8%, n = 15), cefoxitin 
(28.8%, n = 15), aztreonam (36.5%, n = 19), and 
polymyxin B (23.1%, n = 12) in hospitalized preterm 
infants. Among all the strains, 20 isolates of  E. 
coli were resistant to more than three antibiotics 
categorized as multidrug-resistant (MDR) (Yap et al., 
2016). In another study in 2015, ampicillin showed the 
highest resistance to 67% compared to 68.9% in 2013. 
The least resistance by meropenem (0.5%) in 2015 had 
slightly increased to 0.9% in 2016 and reduced to 0.7% 
in 2017. In blood samples, cefuroxime and cefotaxime 
resistance rate rose to 25.4% and 25.9% in 2015 
respectively. According to National surveillance of 
antibiotic resistance, Malaysia, the resistance rate of 
cephalosporins (cefuroxime 25.9% and cefotaxime 
25.4%) has slightly increased in 2017 compared to 
23.5% and 23.4% respectively in 2016. Even though 
imipenem (0.8%) and meropenem (0.7%) resistance 
rate were low in 2017, but an increasing trend of 
resistance was observed between 2010 and 2017 
(Figure 4). 
Among the tested antibiotics, cefuroxime (25.9%) 
showed the highest resistant to E. coli while least 
resistance by meropenem (0.7%) in 2017. Moreover, 
cefotaxime (25.4%), ciprofloxacin (24.1%) and 
ceftazidime (17.7%) were the highest resistance to E. 
coli from 2013 to 2017. The resistance trends of 
antibiotic has increased as well as decreased against 
E.coli from 2010 to 2017 ( Figure 3) (M. o. H. Institute 
for Medical Research, Malaysia, 2017, 21st 
September,). 
Since 2009 to 2017, it was reported about E. coli 
resistance against various antibiotics. Among all the 
used antibiotics, ampicillin showed the highest 
resistant (77%) followed by ceftriaxone (42.30%) and 
cefuroxime (25.9%). The least resistance was 
observed by meropenem 0.2% between 2009 and 2017 
(Table 3). 
The highest resistance trends were shown among 
the different types of the antibiotic to bacteria (E. coli, 
Acinetobacter spp., Klebsiella spp., P. aeruginosa) 
last 5 years (2013 to 2017) based on National 
surveillance of antibiotic resistance, Malaysia, 2017 
(Figure 5). Among all the tested antibiotics, 
meropenem have shown the highest resistance rate of 
58.6%, 63.2%, 60.6% and 61.1% to Acinetobacter 
spp. while lowest resistance rate of 0.3%, 0.2%, 0.5%, 
0.9% and 0.7% to E. coli between 2013 to 2017. 
Moreover, imipenem (61.1%), ceftazidime (58%), 
ampicillin/sulbactam (57.1%), gentamicin (53.2%) 
and amikacin (49.8%) showed the highest resistance 
to Acinetobacter spp. past 5 years (2013 to 2017). In 
2017, Meropenem (0.7%) were least resistance to 
E.coli while amikacin (3.5%) to Pseudomonas 
aeruginosa, polymixin B (0%) to Acinetobacter spp. 
and imipenem  (2.7%) to Klebsiella pneumoniae (M. 
o. H. Institute for Medical Research, Malaysia, 2017, 
15th September).   
The antibiotic resistance trends among the 
Klebsiella spp., imipenem (80%) showed the highest 
increasing resistance trends followed by meropenem 
(71%), amikacin (53%), cefepime (40%), and 
amoxicillin/clavulanic acid (21%). In addition, 
gentamicin showed a decrease resistance trend by 19% 
followed by ciprofloxacin 1% between 2013 and 2017. 
In E. coli. isolates imipenem (167%) showed the 
highest increasing resistance trends followed by 
meropenem (133%), amikacin (88%), cefepime 
(32%), gentamicin (27%) and amoxicillin/clavulanic 
acid (21%) between 2013 and 2017. Among the most 
commonly prescribed antibiotics, ceftazidime (106%) 
showed the highest increasing resistance trends 
followed by cefoperazone/ sulbactam (18%), amikacin 
(14%), imipenem (13%), and gentamicin (11%) to 
Acinetobacter spp. between 2013 and 2017. In 
addition, polymyxin B showed a decrease resistance 
trend by 100%. In P. aeruginosa, amikacin showed an 
increasing resistance trend by 21% while cefepime 
was 8% since 2013 to 2017. Rest of the antibiotics 
(Meropenem 20%, ceftazidime 14%, and gentamicin 
3%) showed a decrease resistance trend between 2013 
and 2017 (Figure 5). 
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Haemophilus influenzae  
Haemophilus influenzae is an indigenous 
bacterium of the upper respiratory tract infection and 
also with Streptococcus pneumonia can cause 
respiratory tract infections (Seyama et al., 2016). The 
highest resistance rate was observed for trimethoprim/ 
sulfamethoxazole (41.4 %) to Haemophilus influenzae 
in 2015.  The least resistance to cefotaxime (2.9 %) in 
2015 has decreased compared to 5.3% in 2013. A 
report by NSAR, Malaysia revealed that ampicillin 
resistance increased to 25.7% in 2015 compared to 
23.2% in 2014 while cefuroxime rose to 5.5% in 2015 
compared to 2.5% in 2014 and 
trimethoprim/sulfamethoxazole decreased to 41.4% in 
2015 compared to 45.5% in 2014 (M. o. H. Institute 
for Medical Research, Malaysia,, 2016).  
Salmonella 
Salmonella spp. is a well-known pathogen causes 
different types of infection by  
consumption of contaminated food that leads to 
thousands of deaths per year globally (Calayag, 
Paclibare, Santos, Bautista, & Rivera, 2017). National 
surveillance of antibiotic resistance, Malaysia reported 
that there was a reduction in the resistance rates to 
ampicillin (6%), chloramphenicol (1.5%), ceftriaxone 
(0.3%), and trimethoprim/sulfamethoxazole (5.3%) in 
2015 compared to 2014. In addition, resistance to 
ceftriaxone was 0% in 2013. Ciprofloxacin resistance 
was observed to be markedly reduced to 4.6% in 2017 
compared to 8.3% in 2016. Ciprofloxacin showed a 
decreasing trend of resistance (45%) between 2013 
and 2017. In 2017, Chloramphenicol, Ciprofloxacin, 
and Co-trimoxazole showed a resistance rate of 2.2 %, 
4.6% and 5.4% respectively (M. o. H. Institute for 
Medical Research, Malaysia, 2017, 15th September).   
Moreover, a Recent study from clinical isolates of 
Selayang hospital in Malaysia reported that 
nontyphoidal Salmonella (NTS) isolates demonstrated 
18.4%, 10.5% and 2.6% resistance towards ampicillin, 
trimethoprim-sulfamethoxazole, and ciprofloxacin 
respectively (Abu et al., 2016).  
Among the recent studies in Malaysia, 
nontyphoidal Salmonella (NTS) isolates were 
resistance to ampicillin (18.4%) while 13% resistance 
in 2017 (M. o. H. Institute for Medical Research, 
Malaysia, 2017, 15th September). This ampicillin 
resistance of 18.4% could be an alarming issue and 
need further monitoring. 
Neisseria gonorrhea 
 
Gonorrhea is a sexually transmitted infection (STI) 
caused by variable strains Neisseria gonorrhoeae, and 
worldwide it is a worrisom matters in public health 
priority (Wi et al., 2017). A study of NSRA reported 
that Penicillin resistance has slightly reduced to 51.6% 
in 2015 compared to 52.7% in 2014. During the last 5 
years (2013-2017), tetracycline showed the highest 
resistance rate of 84.7% to Neisseria gonorrhea in 
2015 while 82% in 2017. The resistance rate of 
ceftriaxone has slightly reduced to 2.1% in 2017 from 
2.2% in 2013. Moreover, the resistance rate of 
ciprofloxacin and tetracycline has increased by 7% 
and 5% respectively between 2013 to 2017 (M. o. H. 
Institute for Medical Research, Malaysia, 2017, 15th 
September) In addition, the resistance rate for 
penicillin was 23.5 % in 2010 compared to 61% in 
2007 (Lahra, 2012).  
4. Conclusions 
Among all the observed gram-negative bacteria 
over the years, an increasing trend of antibiotic 
resistance has revealed the prevalence rate of 
antibiotic resistance which leads to this study for a 
review. Thousands of bacterial isolates were examined 
from different place and locations all over Malaysia. 
Findings from this preliminary study indicated the 
prevalence rate  of antibiotic-resistant bacteria in 
Peninsular Malaysia. The outcome of this study can be 
efficient on infection control measures, and antibiotic 
stewardship programs should be able to control the 
spread of the multidrug-resistant bacteria. This could 
be a proper guideline for appropriate antibiotics to use 
against gram-negative bacteria. The Most frequent 
antibiotic resistance profiles were observed by 
ampicillin, piperacillin, ceftazidime, and tetracycline, 
etc. regardless in Malaysia. The presence of multidrug 
resistant bacteria is a significant concern in human 
health.  
In summary, an increasing trend of antibiotic 
resistance observed over the years. The emergence and 
increase of antimicrobial resistance are a constant 
threat and challenge to control infections in Malaysia. 
The epidemiological infections due to antimicrobial-
resistant bacteria have emerged in Malaysia. This 
study provides a scenario of recent antimicrobial uses 
all over Malaysia and this will be an aid to reduce 
acquisition of MDR. Limited infection control 
measures, lack of antimicrobial control, and travel 
throughout this region have likely contributed to the 
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increase in multidrug resistant gram negavtive 
(MDRGN) prevalence. A continuous surveillance 
programme establishment might help in minimizing 
such infections. Thus, improving infection control 
practices, laboratory detection, judicious use of 
antimicrobial agents, and national surveillance could 
have an impact on antibiotic resistance as well as 
MRD spread in Malaysia.  
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Table 1: The antibiotic resistance rates of Acinetobacter species isolates 
Year  Antibiotics Highest 
Resistance % 
Source 
2014 Tetracycline 87% Soo-Sum Lean et al. 
2012 Meropenem 92.5% Nazmul et al. 
2015 Meropenem 58.8% *NSAR 
2016 Meropenem 60.8% *NSAR 
2016 Cephalexin 95.45% S.Y. Ng et al. 
2017 Imipenem, Ceftazidime, Cefuroxime - Selvi et al., 
 Ceftriaxone 100%  
2016 Polymyxin B, Ampicillin/sulbactam, ceftazidime, 
etc 
- Nathan et al. 
 2007 Imipenem, Ceftazidime, Cefuroxime etc -  Palasubramaniam et al. 
2017 Meropenem 61.1% *NSAR 
*NSAR: National Surveillance of Antimicrobial Resistance, Malaysia 
 
 
Table 2: The highest antibiotic resistance rates of Klebsiella spp. among all the clinical isolates 
Year  Antibiotics Resistance % Source 
2017 Tetracycline - Low et al. 
2015 Ampicillin 84.3% Nor et al 
2015 
  
Ampicillin 100% Farah et al. 
  
Aztreonam 100%  
Cefoperazone 100%  
2015 Gentamicin 74% Al-Marzooq et 
al 
Trimethoprim/sulfamethoxazole 90.3%  
 2015 Cephalosporin groups - Nurul et al 
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Table 3: The antibiotic resistance rates of Escherichia coli isolated 
Year  Antibiotics Highest Resistance % Least Resistance % Source 
2009 Ampicillin 77   Lim et al 
  Amikan  2   
2013 Ampicillin 68.9   *NSAR 
  Meropenem  0.3   
2014 Ampicillin 66.20   *NSAR 
  Meropenem  0.2   
2015 Ampicillin 67   *NSAR 
  Meropenem  0.50   
 2015 Ampicillin 67.70   Nor et al 
  Gentamicin  7.30   
2016 Ceftriaxone 42.30   Poly et al 
  Polymyxin B  23.1   
2017 Cefuroxime 25.9  *NSAR 
 Imipenem  0.8  
    *NSAR: National Surveillance of Antimicrobial Resistance, Malaysia 
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Figure 1: Antibiotic resistance trends of Acinetobacter spp. (2010-2017) 
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Figure 2: The antibiotic resistance rates of Pseudomonas aeruginosa species isolated *NSAR: National 
Surveillance of Antimicrobial Resistance, Malaysia 
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Figure 3: Antibiotic resistance trends on Pseudomonas aeruginosa (2010-2017) 
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Figure 4: Antibiotic resistance trends of Klebsiella spp. (2010-2017) 
 
Figure 5: Antibiotic resistance trends of E. coli (2010-2017) 
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Figure 6: Antibiotic resistance trends among the most dominant bacteria 
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